Study Finds Affordable Three-Drug Combination Improves Outcomes in Relapsed/Refractory Multiple Myeloma

A new phase III study by the Asian Myeloma Network (AMN) found that adding the affordable chemotherapy drug Cytoxan® (cyclophosphamide) to the standard treatment of Pomalyst® (pomalidomide) and dexamethasone (PD) significantly improved outcomes for patients with relapsed or refractory multiple myeloma (RRMM). The study, known as AMN003, enrolled 122 patients across five Asian countries who had already been treated with Revlimid® (lenalidomide) and a proteasome inhibitor such as Velcade® (bortezomib). Patients who received the three-drug combination (PCD) had a median progression-free survival (PFS) of 10.9 months, nearly double that of those treated with PD alone (5.8 months). The overall response rate (ORR) was also higher with PCD—61% compared to 38%. These improvements were achieved without more serious side effects.

What This Means

The PCD regimen (pomalidomide, cyclophosphamide, and dexamethasone) offers a safer, more effective, and affordable option for people with relapsed or refractory myeloma. Side effects were manageable and similar to those seen with standard treatment. This makes PCD a strong alternative for patients who have already received multiple lines of therapy and are looking for new treatment options that balance efficacy, safety, and cost.

Why This Matters

Access to advanced therapies like CAR T-cell treatment and bispecific antibodies remains limited and expensive in many parts of Asia and other regions worldwide. The results of the AMN003 study show that an accessible, oral, and low-cost combination can still deliver meaningful clinical benefits. By improving survival without adding toxicity or financial burden, the PCD regimen could become a new standard treatment for relapsed myeloma patients, helping to close the global gap in cancer care access.

To learn more about this study, read the publication in Nature from the button below.